Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:

CareDx, Inc CDNA: This diagnostic solutions company for transplant patients and caregivers has seen the Zacks Consensus Estimate for its current year earnings increasing 7.5% over the last 60 days.

CareDx, Inc. Price and Consensus

CareDx, Inc. price-consensus-chart | CareDx, Inc. Quote

Alnylam Pharmaceuticals, Inc. ALNY: This biopharmaceutical company has seen the Zacks Consensus Estimate for its current year earnings increasing 20.4% over the last 60 days.

Alnylam Pharmaceuticals, Inc. Price and Consensus

Alnylam Pharmaceuticals, Inc. price-consensus-chart | Alnylam Pharmaceuticals, Inc. Quote

ICL Group Ltd ICL: This specialty minerals and chemicals company has seen the Zacks Consensus Estimate for its next year earnings increasing 8.8% over the last 60 days.

ICL Group Ltd. Price and Consensus

ICL Group Ltd. price-consensus-chart | ICL Group Ltd. Quote

Anavex Life Sciences Corp. AVXL: This clinical stage biopharmaceutical company has seen the Zacks Consensus Estimate for its current year earnings increasing 8.8% over the last 60 days.

Anavex Life Sciences Corp. Price and Consensus

Anavex Life Sciences Corp. price-consensus-chart | Anavex Life Sciences Corp. Quote

Alcoa Corporation AA: This company that produces and sells bauxite, alumina, and aluminum products has seen the Zacks Consensus Estimate for its current year earnings increasing 21.4% over the last 60 days.

Alcoa Price and Consensus

Alcoa price-consensus-chart | Alcoa Quote

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Alnylam Pharmaceuticals, Inc. (ALNY) : Free Stock Analysis Report

Alcoa (AA) : Free Stock Analysis Report

ICL Group Ltd. (ICL) : Free Stock Analysis Report

Anavex Life Sciences Corp. (AVXL) : Free Stock Analysis Report

CareDx, Inc. (CDNA) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research